SHigh-dose interleukin-2 (IL-2) results in objective clinical regression of metastatic cancer in 15% to 17% of patients with melanoma and renal cell carcinoma. Durable complete regression of all metastases is seen in 6% to 8% of patients. Based on these findings, the U.S. Food and Drug Administration has approved the use of high-dose IL-2 for the treatment of patients with metastatic melanoma and renal cell carcinoma. Interleukin-2 administration is associated with many different side effects, and after many years of use, clinicians have learned how to safely administer high-dose IL-2. It is so toxic as to require an ICU or similar unit to be able to “carry” the patient through skin, kidney, GI toxicity.
Schwartzentruber DJ. Guidelines for the safe administration of high-dose interleukin-2.J.Immunother. 2001 Jul-Aug;24(4):287-93.
Schwartz RN, Stover L, Dutcher J. Managing toxicities of high-dose interleukin-2.Oncology (Williston Park). 2002 Nov;16(11 Suppl 13):11-20.